1. Home
  2. PBM vs CDT Comparison

PBM vs CDT Comparison

Compare PBM & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBM
  • CDT
  • Stock Information
  • Founded
  • PBM 1994
  • CDT 2019
  • Country
  • PBM Canada
  • CDT United States
  • Employees
  • PBM N/A
  • CDT N/A
  • Industry
  • PBM
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBM
  • CDT Health Care
  • Exchange
  • PBM NYSE
  • CDT Nasdaq
  • Market Cap
  • PBM 5.3M
  • CDT 5.3M
  • IPO Year
  • PBM N/A
  • CDT N/A
  • Fundamental
  • Price
  • PBM $3.88
  • CDT $0.40
  • Analyst Decision
  • PBM
  • CDT
  • Analyst Count
  • PBM 0
  • CDT 0
  • Target Price
  • PBM N/A
  • CDT N/A
  • AVG Volume (30 Days)
  • PBM 49.3K
  • CDT 6.7M
  • Earning Date
  • PBM 05-20-2025
  • CDT 05-13-2025
  • Dividend Yield
  • PBM N/A
  • CDT N/A
  • EPS Growth
  • PBM N/A
  • CDT N/A
  • EPS
  • PBM N/A
  • CDT N/A
  • Revenue
  • PBM N/A
  • CDT N/A
  • Revenue This Year
  • PBM N/A
  • CDT N/A
  • Revenue Next Year
  • PBM N/A
  • CDT N/A
  • P/E Ratio
  • PBM N/A
  • CDT N/A
  • Revenue Growth
  • PBM N/A
  • CDT N/A
  • 52 Week Low
  • PBM $0.41
  • CDT $0.51
  • 52 Week High
  • PBM $824.90
  • CDT $350.00
  • Technical
  • Relative Strength Index (RSI)
  • PBM 44.18
  • CDT 31.05
  • Support Level
  • PBM $2.99
  • CDT $0.37
  • Resistance Level
  • PBM $4.80
  • CDT $0.57
  • Average True Range (ATR)
  • PBM 0.68
  • CDT 0.05
  • MACD
  • PBM 0.18
  • CDT 0.01
  • Stochastic Oscillator
  • PBM 47.52
  • CDT 12.30

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: